Celera (NASDAQ:CRA) today announced the appointment of K. Scott Bland to the new position of Vice President of Sales at its Berkeley HeartLab, or BHL, subsidiary. The appointment is effective immediately and Mr. Bland will report to Chris Hall, Chief Business Officer of BHL.

Mr. Bland has been a regional director of sales at BHL, providing oversight to sales activities in the southeast of the United States for the last two years. Prior to joining BHL, Mr. Bland was a regional business advisor for Allergan Pharmaceuticals, and he also held various sales and management positions in cardiovascular disease with Kos Pharmaceuticals before the company was sold to Abbott. Mr. Bland received his B.S. and his M.B.A. degrees from The Citadel in Charleston, South Carolina.

“Scott adds a tremendous wealth of experience in cardiovascular disease management to our team at Berkeley HeartLab,” said Chris Hall, Chief Business Officer of Berkeley HeartLab. “We’ve experienced substantial growth and expansion at BHL, and as a result there’s a need to strengthen our commercial infrastructure. This new position goes a long way toward achieving this, and with a strong customer focus and a deep knowledge of the cardiovascular disease industry, we think Scott is well positioned to lead our sales efforts to deliver on our vision of personalizing disease management.”